OLD Category: Oncology

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

• Kim SB et al.,

Should a Multigene Signature be Used in all Luminal Early Breast Cancers

• Hajjaji N et al.,

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial

• Gluz O et al.,

Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group

• Eder T et al.,

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

• Picornell AC et al.,

Immune signature profiling identified prognostic factors for gastric cancer

• Yang W et al.,

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma

• Stromnes IM et al.,

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

• Rozeman EA et al.,

Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity

• Bodelon C et al.,

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma

• Ghatalia P et al.,

Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas

• Hess AK, Jöhrens K, Zakarneh A, Keilholz U, Budach V, Tinhofer I

Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial

• Ji N et al.,